Video - Results from #40

ASCO 2024 VL

CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li Details Ashish Kamat hosts a discussion with Roger Li and Trinity Bivalacqua on the CORE-001 study evaluating cretostimogene grenadenorepvec and pembrolizumab for BCG-unresponsive CIS. Dr. Li highlights the 83% complete response rate at any time, 57.1% at 12 months, and 54.3% at 24 months, noting the therapy's durability and lack of progression to muscle-invasive or metastatic disease. The combination the...
Behavioral Interventions for Mitigating ADT Side Effects in Prostate Cancer - Brian Gonzalez Details Alicia Morgans interviews Brian Gonzalez about his talk at ASCO 2024 on behavioral interventions to mitigate the adverse effects of androgen deprivation therapy (ADT) for prostate cancer patients. Dr. Gonzalez explains that cognitive behavioral therapy (CBT) and physical activity interventions are effective in improving side effects like fatigue, sleep issues, and vasomotor symptoms. He highlights...